Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
- Author(s)
- Mitri, EA; Fletcher, LR; Vogrin, S; Barnes, S; Powell, N; Peter, J; Li, PH; Copaescu, AM; Turner, NA; James, F; Paynter, C; Sullivan, R; Masoum, MS; Rawlins, M; Mackay, G; Smith, BJ; Kilfoyle, P; Forster, D; Rose, M; Cowan, R; Alcorn, K; Brischetto, A; Mahony, A; Redmond, A; Chakravorty, A; Meher-Homji, Z; Yuson, C; Crawford, S; Weeks, G; Ponnampalavanar, SSS; Katelaris, C; Tran, P; O'Hern, J; Godsell, J; Peel, TN; Sandaradura, I; New, D; Holland, C; Cutfield, T; Coghill, S; Hand, C; Williams, J; Bishop, J; Lambros, B; Day, C; Ierano, C; Roberts, JA; Holmes, NE; Klaic, M; Fernando, SL; Trubiano, JA; International Network of Antibiotic Allergy Nations (iNAAN) Study Group;
- Journal Title
- Clinical Infectious Diseases
- Publication Type
- Online publication before print
- Abstract
- BACKGROUND: Approximately 10% of hospitalized patients globally report a penicillin allergy, leading to inappropriate antibiotic prescribing and inferior healthcare outcomes. Evidence supporting the effectiveness and widespread implementation of inpatient penicillin direct oral challenge (DOC) is limited. METHODS: A prospective, multicenter, international type 2 hybrid effectiveness-implementation study was conducted in 40 hospitals across 8 countries between November 2022 and May 2025. Adult inpatients with a penicillin allergy underwent assessment using a digital penicillin allergy toolkit (National Antibiotic Allergy Network [NAAN] App). According to site clinical practice, participants received penicillin DOC (effectiveness intervention) or assessment only. Participating sites received bimonthly audit and feedback at least 3 months after site activation (implementation strategy). Observational data were used to emulate a target trial to examine secondary effectiveness outcomes, including antibiotic prescribing at 90 days in DOC versus non-DOC participants. The primary implementation outcome was adoption of the NAAN App within 6 months of site activation. RESULTS: Among 5121 participants assessed, 1573 (30.7%) underwent DOC, of which 1502 (95.5%) were delabeled. Of 71 (4.5%) participants with a positive DOC, 6 (0.4%) had a serious adverse event. Of 1852 inpatients in the target trial analysis, 892 underwent DOC and 960 underwent assessment only. Participants who underwent DOC were more likely to be prescribed penicillin (risk ratio [RR], 13.25 [95% confidence interval {CI}, 7.82-22.46]), and less likely to be prescribed World Health Organization (WHO) "Watch" or "Reserve" antibiotics (RR, 0.73 [95% CI, .60-.89]) at 90 days post evaluation. Within 6 months of site activation, 77 clinicians adopted the NAAN App. CONCLUSIONS: Multidisciplinary adoption of inpatient penicillin DOC was safe and significantly improved penicillin prescribing and reduced use of WHO restricted antibiotics.
- Keywords
- allergy; antibiotic allergy; antimicrobial stewardship; delabeling; direct oral challenge
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1093/cid/ciag082
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-04-14 03:18:20
Last Modified: 2026-04-14 03:18:35